NuCana Extends Cash Runway into 2029, Reports Positive Phase 2 Melanoma Data for NUC-7738, Plans FDA Guidance
summarizeSummary
NuCana announced its Q4 and full-year 2025 financial results, highlighting a significantly extended cash runway into 2029, a critical update for a development-stage biotech. The company also provided a positive business update on its lead anti-cancer medicine, NUC-7738, reporting favorable safety and clinical activity, including two partial responses and one complete metabolic response, in a Phase 2 expansion study for PD-1 inhibitor-resistant melanoma. Management plans to seek regulatory guidance from the FDA regarding a potential registrational pathway for NUC-7738 in melanoma, signaling a significant step towards commercialization. While the company reported increased net losses for the quarter and year, the strong cash position, bolstered by prior financings, and the promising clinical and regulatory progress are key positive catalysts for the stock. Investors will now watch for the final data from the Phase 2 study and the outcome of discussions with the FDA.
At the time of this announcement, NCNA was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $1.63 to $268.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.